Hemoglobin M (HbM) is a variant where histidine is replaced by tyrosine at the F8 or E7 positions, stabilizing iron in the ferric (Fe3+) state. Patients present with cyanosis from birth that does not respond to methylene blue. Why does methylene blue fail to treat methemoglobinemia in HbM?

• A HbM iron is stabilized by a covalent bond between tyrosine and the heme iron that cannot be disrupted by methylene blue-mediated reduction ✓
• B Methylene blue cannot cross the red blood cell membrane in HbM patients
• C Methylene blue reduces MetHb via NADPH-methemoglobin reductase, but the tyrosine in HbM re-oxidizes iron spontaneously faster than the rate of reduction
• D HbM patients have normal NADPH-methemoglobin reductase but lack cytochrome b5 reductase

Explanation

In HbM variants, the tyrosine oxygen forms a strong coordinate bond (essentially covalent-like) with the heme iron, stabilizing it permanently in the Fe3+ (ferric/methemoglobin) state. Methylene blue works in acquired methemoglobinemia by activating NADPH-methemoglobin reductase (after being reduced to leucomethylene blue by G6PD-generated NADPH), which then reduces Fe3+ to Fe2+. However, in HbM, the tyrosine-iron bond is not disrupted by this reduction pathway because the structural constraint of the tyrosine coordination immediately re-oxidizes iron — or more precisely, the ferric state is thermodynamically stabilized and cannot be reduced by this mechanism. Treatment is supportive; patients are generally asymptomatic despite cyanosis because oxygen affinity of remaining HbA chains compensates.

Reference: Harper's Illustrated Biochemistry, 32nd ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.